Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/CD44_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/CD44_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/CD44_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/CD44_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/CD44_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CD44_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CD44_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/CD44_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CD44_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CD44_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CD44_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CD44_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00182126 | Thyroid | PTC | peptidyl-tyrosine modification | 142/5968 | 378/18723 | 1.02e-02 | 4.14e-02 | 142 |
GO:00331384 | Thyroid | PTC | positive regulation of peptidyl-serine phosphorylation | 46/5968 | 108/18723 | 1.22e-02 | 4.78e-02 | 46 |
GO:19021666 | Thyroid | PTC | negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 9/5968 | 14/18723 | 1.27e-02 | 4.92e-02 | 9 |
GO:200123335 | Thyroid | ATC | regulation of apoptotic signaling pathway | 206/6293 | 356/18723 | 2.81e-21 | 5.92e-19 | 206 |
GO:009719335 | Thyroid | ATC | intrinsic apoptotic signaling pathway | 171/6293 | 288/18723 | 1.86e-19 | 2.67e-17 | 171 |
GO:003158928 | Thyroid | ATC | cell-substrate adhesion | 195/6293 | 363/18723 | 1.58e-15 | 1.17e-13 | 195 |
GO:002260429 | Thyroid | ATC | regulation of cell morphogenesis | 171/6293 | 309/18723 | 2.36e-15 | 1.70e-13 | 171 |
GO:200124233 | Thyroid | ATC | regulation of intrinsic apoptotic signaling pathway | 103/6293 | 164/18723 | 1.67e-14 | 9.77e-13 | 103 |
GO:007233135 | Thyroid | ATC | signal transduction by p53 class mediator | 102/6293 | 163/18723 | 3.16e-14 | 1.75e-12 | 102 |
GO:2001234210 | Thyroid | ATC | negative regulation of apoptotic signaling pathway | 129/6293 | 224/18723 | 1.26e-13 | 6.46e-12 | 129 |
GO:190179635 | Thyroid | ATC | regulation of signal transduction by p53 class mediator | 66/6293 | 93/18723 | 1.86e-13 | 9.20e-12 | 66 |
GO:004206034 | Thyroid | ATC | wound healing | 210/6293 | 422/18723 | 3.33e-12 | 1.37e-10 | 210 |
GO:0007160111 | Thyroid | ATC | cell-matrix adhesion | 128/6293 | 233/18723 | 1.49e-11 | 5.41e-10 | 128 |
GO:200102026 | Thyroid | ATC | regulation of response to DNA damage stimulus | 121/6293 | 219/18723 | 3.22e-11 | 1.08e-09 | 121 |
GO:200124333 | Thyroid | ATC | negative regulation of intrinsic apoptotic signaling pathway | 63/6293 | 98/18723 | 4.97e-10 | 1.33e-08 | 63 |
GO:001810519 | Thyroid | ATC | peptidyl-serine phosphorylation | 153/6293 | 315/18723 | 2.28e-08 | 4.42e-07 | 153 |
GO:007233233 | Thyroid | ATC | intrinsic apoptotic signaling pathway by p53 class mediator | 49/6293 | 76/18723 | 3.60e-08 | 6.67e-07 | 49 |
GO:001820917 | Thyroid | ATC | peptidyl-serine modification | 161/6293 | 338/18723 | 5.23e-08 | 9.44e-07 | 161 |
GO:004277016 | Thyroid | ATC | signal transduction in response to DNA damage | 90/6293 | 172/18723 | 3.01e-07 | 4.52e-06 | 90 |
GO:003033033 | Thyroid | ATC | DNA damage response, signal transduction by p53 class mediator | 45/6293 | 72/18723 | 4.87e-07 | 7.03e-06 | 45 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CD44 | SNV | Missense_Mutation | | c.106G>A | p.Val36Met | p.V36M | P16070 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A2-A0ET-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
CD44 | SNV | Missense_Mutation | novel | c.1934C>T | p.Pro645Leu | p.P645L | P16070 | protein_coding | deleterious(0) | possibly_damaging(0.541) | TCGA-B6-A0I9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
CD44 | SNV | Missense_Mutation | | c.829G>C | p.Glu277Gln | p.E277Q | P16070 | protein_coding | tolerated(0.18) | benign(0.32) | TCGA-D8-A143-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
CD44 | insertion | Nonsense_Mutation | novel | c.1935_1936insATCATATAATCTCAATGCAATAAATAATCAA | p.Gln646IlefsTer3 | p.Q646Ifs*3 | P16070 | protein_coding | | | TCGA-B6-A0I9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
CD44 | deletion | Frame_Shift_Del | | c.1454_1461delCAAATCCA | p.Ala485GlufsTer22 | p.A485Efs*22 | P16070 | protein_coding | | | TCGA-C8-A1HJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CD44 | SNV | Missense_Mutation | novel | c.476N>C | p.Gly159Ala | p.G159A | P16070 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-DG-A2KM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
CD44 | SNV | Missense_Mutation | | c.1521N>C | p.Gln507His | p.Q507H | P16070 | protein_coding | deleterious(0.02) | possibly_damaging(0.707) | TCGA-FU-A23K-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
CD44 | SNV | Missense_Mutation | rs371026548 | c.1289C>T | p.Ser430Leu | p.S430L | P16070 | protein_coding | deleterious(0.02) | benign(0.154) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CD44 | SNV | Missense_Mutation | novel | c.1790N>C | p.Asn597Thr | p.N597T | P16070 | protein_coding | deleterious(0.01) | benign(0.025) | TCGA-VS-A9U5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CD44 | SNV | Missense_Mutation | | c.92N>T | p.Ala31Val | p.A31V | P16070 | protein_coding | deleterious(0) | benign(0.329) | TCGA-AA-A01I-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
960 | CD44 | DRUGGABLE GENOME, CELL SURFACE | | GENTAMICIN | GENTAMICIN | 14967965 |
960 | CD44 | DRUGGABLE GENOME, CELL SURFACE | | MPA | PROGESTERONE | 11605071 |
960 | CD44 | DRUGGABLE GENOME, CELL SURFACE | | RG7356 | | 25762343 |
960 | CD44 | DRUGGABLE GENOME, CELL SURFACE | | TUMOR NECROSIS FACTOR | | 12867430 |
960 | CD44 | DRUGGABLE GENOME, CELL SURFACE | | GP-120 | | 7539755 |
960 | CD44 | DRUGGABLE GENOME, CELL SURFACE | | INTERFERON GAMMA | | 11369659 |
960 | CD44 | DRUGGABLE GENOME, CELL SURFACE | | HYALURONAN | HYALURONAN | |
960 | CD44 | DRUGGABLE GENOME, CELL SURFACE | | MOMETASONE FUROATE | | 12877820 |
960 | CD44 | DRUGGABLE GENOME, CELL SURFACE | | A-6 | | |
960 | CD44 | DRUGGABLE GENOME, CELL SURFACE | | BIWA 4 | | |